Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) recorded Income from Continuing Operations of $164.49 million in Q2 2026, compared with -$72.23 million a year earlier and down 20.1% from the prior quarter.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
On a TTM basis, Alnylam Pharmaceuticals' Income from Continuing Operations came in at $774.71 million as of Jun 30, 2026; for FY2025, it came in at $313.75 million.
- Across earlier years, Income from Continuing Operations came in at -$278.16 million in FY2024, -$440.24 million in FY2023, -$1.13 billion in FY2022 and -$852.82 million in FY2021.
- Quarterly Income from Continuing Operations has ranged from -$405.92 million in Q3 2022 to $292.68 million in Q3 2025 over the past five years.
- Per Business Quant, the preceding three quarters came in at $205.99 million (Q1 2026), $111.54 million (Q4 2025) and $292.68 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.54 Bn | 572.07 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 467.01 Bn | 440.17 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 367.16 Bn | 321.59 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 277.56 Bn | 233.43 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 258.23 Bn | 231.79 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 224.14 Bn | 179.54 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 187.30 Bn | 161.42 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 163.47 Bn | 110.41 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 133.31 Bn | 105.31 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Alnylam Pharmaceuticals | 34.23 Bn | 22.28 Bn | 992.69 Mn | 164.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 164.49 Mn |
| Mar 31, 2026 | 205.99 Mn |
| Dec 31, 2025 | 111.54 Mn |
| Sep 30, 2025 | 292.68 Mn |
| Jun 30, 2025 | -72.23 Mn |
| Mar 31, 2025 | -18.25 Mn |
| Dec 31, 2024 | -83.76 Mn |
| Sep 30, 2024 | -111.57 Mn |
| Jun 30, 2024 | -16.89 Mn |
| Mar 31, 2024 | -65.94 Mn |
| Dec 31, 2023 | -137.87 Mn |
| Sep 30, 2023 | 147.75 Mn |
| Jun 30, 2023 | -276.02 Mn |
| Mar 31, 2023 | -174.10 Mn |
| Dec 31, 2022 | -207.49 Mn |
| Sep 30, 2022 | -405.92 Mn |
| Jun 30, 2022 | -277.40 Mn |
| Mar 31, 2022 | -240.34 Mn |
| Dec 31, 2021 | -258.46 Mn |
| Sep 30, 2021 | -204.51 Mn |
API Access
Alnylam Pharmaceuticals Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=ALNY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "ALNY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=ALNY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();